Table: Takeda Pharma -2025/26 group results (IFRS)

Takeda Pharmaceutical

13/05/2026 07:33

May 13 (Reuters)- 
              Takeda Pharmaceutical Co. Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   Year ended      Year ended       Year to        NEXT  
                Mar 31, 2026    Mar 31, 2025   Mar 31, 2027      YEAR    
                   LATEST         YEAR-AGO        COMPANY      COMPANY   
                   RESULTS         RESULT        FORECAST    H1 FORECAST 
  Sales           4.51 trln       4.58 trln      4.64 trln               
                 (-1.7 pct)      (+7.5 pct)     (+3.0 pct)               
  Operating        408.76          342.59         420.00                 
                 (+19.3 pct)     (+60.0 pct)    (+2.7 pct)               
  Pretax           260.19          175.08         252.00                 
                 (+48.6 pct)    (+231.7 pct)    (-3.1 pct)               
  Net              191.76          107.93         166.00                 
                 (+77.7 pct)     (-25.1 pct)    (-13.4 pct)              
  EPS Basic      121.75 yen       68.36 yen     104.26 yen               
  EPS Diluted    119.64 yen       67.23 yen                              
  Ann Div        200.00 yen      196.00 yen     204.00 yen               
  -Q2 Div        100.00 yen       98.00 yen     102.00 yen               
  -Q4 Div        100.00 yen       98.00 yen     102.00 yen               
 
  NOTE - Takeda Pharmaceutical Co. Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4502.T